TajikistanTuberculosis profile
Population  2014 8.3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.27 (0.2–0.36) 3.3 (2.4–4.4)
Mortality (HIV+TB only) 0.055 (0.039–0.074) 0.66 (0.47–0.89)
Prevalence  (includes HIV+TB) 11 (5.2–18) 128 (63–216)
Incidence  (includes HIV+TB) 7.6 (6.7–8.5) 91 (80–103)
Incidence (HIV+TB only) 0.23 (0.2–0.27) 2.8 (2.4–3.2)
         
Case detection, all forms (%) 77 (68–87)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 8.1 (6.9–9.4) 52 (47–57)
MDR-TB cases among notified pulmonary
TB cases
290 (250–340) 590 (530–650)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 432   540
Pulmonary, clinically diagnosed 1 162   139
Extrapulmonary 1 423   111
       
Total new and relapse 5 807    
Previously treated, excluding relapses 453    
Total cases notified 6 260    
Among 5 807 new and relapse cases:
334 (6%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 432 (100%) 800 (64%) 3 232
Laboratory-confirmed RR-/MDR-TB cases     902
Patients started on MDR-TB treatment ***     804
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 656 (90)
HIV-positive TB patients 161 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 156 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 128 (80)
HIV-positive people screened for TB 3 367  
HIV-positive people provided with IPT 280  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 5 263
Previously treated cases, excluding relapse, registered in 2013 (82) 812
HIV-positive TB cases, all types, registered in 2013 (66) 122
RR-/MDR-TB cases started on second-line treatment in 2012 (66) 535
XDR-TB cases started on second-line treatment in 2012 (100) 1
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 3.0
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 14
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 25
% Funded domestically 28%
% Funded internationally 51%
% Unfunded 21%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-29 Data: www.who.int/tb/data